CHAPEL HILL, N.C., April 15 /PRNewswire/ -- The oncology therapeutic area continues to be a high-growth area targeted by many organizations in the bio-pharmaceutical sector. It's in this competitive environment that organizations with new oncology products are scrutinizing their strategies and tactics to support market education.
To set the stage for a successful launch, it's critical that companies inform thought leaders, physicians, patients and payers about their new oncology products. Best Practices, LLC has published a new report that compares the tactics and strategies for educating these critical four groups for oncology products versus other therapeutic areas.
For instance, commercial executives in the oncology therapeutic area make clinical and compound data disclosures earlier than other therapeutic areas, according to the new report. Forty percent of commercial oncology leaders said they communicate mechanism of action data at pre-clinical whereas only 29 percent of the total study participants said they communicate MOA at that time, according to the study.
Download a complimentary report summary, including sample best practices drawn from extensive primary research with executives at leading companies at: http://www3.best-in-class.com/rr994.htm.
The report, Shaping the Marketplace to Support Successful Oncology Product Launches: Tactics for Educating KOLs, Physicians, Patients and Payers, contains a plethora of benchmark metrics on the most effective physician, payer and patient education practices conducted from clinical development through launch. The 150-page report contains almost 500 metrics to help inform launch leaders in the oncology area on the most effective type and timing of market education practices during the full development cycle.
The research - which includes oncology and total benchmark class segments - attracted 34 executives and managers from 26 leading pharmaceutical, biotech and medical device companies including, GlaxoSmithKline, Novartis, Novo Nordisk, Genentech, Roche, AstraZeneca, Lilly, Abbott and Bayer. Additionally, the research reflects on nine deep-dive interviews with selected participants.
Key Topics of this report include:
To learn more about Best Practices' other timely research visit: http://www3.best-in-class.com or contact Jeff Zimmer at 919-767-9180 or [email protected].
ABOUT BEST PRACTICES, LLC
Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for 17 years; our clients include 46 out of the top 50 pharmaceutical companies. For more information visit: http://www3.best-in-class.com.
SOURCE Best Practices, LLC
Advertisement
To set the stage for a successful launch, it's critical that companies inform thought leaders, physicians, patients and payers about their new oncology products. Best Practices, LLC has published a new report that compares the tactics and strategies for educating these critical four groups for oncology products versus other therapeutic areas.
Advertisement
For instance, commercial executives in the oncology therapeutic area make clinical and compound data disclosures earlier than other therapeutic areas, according to the new report. Forty percent of commercial oncology leaders said they communicate mechanism of action data at pre-clinical whereas only 29 percent of the total study participants said they communicate MOA at that time, according to the study.
Download a complimentary report summary, including sample best practices drawn from extensive primary research with executives at leading companies at: http://www3.best-in-class.com/rr994.htm.
The report, Shaping the Marketplace to Support Successful Oncology Product Launches: Tactics for Educating KOLs, Physicians, Patients and Payers, contains a plethora of benchmark metrics on the most effective physician, payer and patient education practices conducted from clinical development through launch. The 150-page report contains almost 500 metrics to help inform launch leaders in the oncology area on the most effective type and timing of market education practices during the full development cycle.
The research - which includes oncology and total benchmark class segments - attracted 34 executives and managers from 26 leading pharmaceutical, biotech and medical device companies including, GlaxoSmithKline, Novartis, Novo Nordisk, Genentech, Roche, AstraZeneca, Lilly, Abbott and Bayer. Additionally, the research reflects on nine deep-dive interviews with selected participants.
Key Topics of this report include:
- Identification of Key Education Tactics for Thought Leaders, Physicians, Patients, and Payers
- Identification of Key Timing for Educational Activities for KOLs, Physicians, Patients and Payers
- Assessment of Key Market Education Practices, including Thought Leader Activities, CME, Scientific Publication Strategy and Tactics, Patients and Patient Advocacy Education, Clinical Trials & Payer Education
- Description of Critical Market Education Pitfalls and Future Trends
To learn more about Best Practices' other timely research visit: http://www3.best-in-class.com or contact Jeff Zimmer at 919-767-9180 or [email protected].
ABOUT BEST PRACTICES, LLC
Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for 17 years; our clients include 46 out of the top 50 pharmaceutical companies. For more information visit: http://www3.best-in-class.com.
SOURCE Best Practices, LLC
